[{"id":"fc105a8e-84e2-4314-a975-56086a41c786","acronym":"","url":"https://clinicaltrials.gov/study/NCT04440956","created_at":"2021-02-11T16:55:12.622Z","updated_at":"2024-07-02T16:36:43.938Z","phase":"Phase 1","brief_title":"An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine Tumours","source_id_and_acronym":"NCT04440956","lead_sponsor":"Clarity Pharmaceuticals Ltd","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Sartate (67Cu MeCOSar octreotate)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 05/21/2015","start_date":" 05/21/2015","primary_txt":" Primary completion: 02/25/2016","primary_completion_date":" 02/25/2016","study_txt":" Completion: 02/25/2016","study_completion_date":" 02/25/2016","last_update_posted":"2020-06-22"},{"id":"d98ff5d6-925d-43e6-bcc2-7274e5cffa2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03936426","created_at":"2021-02-11T16:53:54.174Z","updated_at":"2024-07-02T16:36:45.846Z","phase":"Phase 1/2","brief_title":"Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™","source_id_and_acronym":"NCT03936426","lead_sponsor":"Clarity Pharmaceuticals Ltd","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Sartate (67Cu MeCOSar octreotate)"],"overall_status":"Completed","enrollment":" Enrollment 5","initiation":"Initiation: 07/09/2018","start_date":" 07/09/2018","primary_txt":" Primary completion: 09/19/2019","primary_completion_date":" 09/19/2019","study_txt":" Completion: 09/19/2019","study_completion_date":" 09/19/2019","last_update_posted":"2020-04-20"}]